ClinicalTrials.gg

Program

follitropin delta

Also written as “Follitropin delta”, “FE 999049” and “Follitropin Delta (FE 999049)”.

Its studies are mostly in Infertility · Infertility, Female, led by 3 companies.

Furthest: phase 3, since Aug 16, 201318 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ferring Pharmaceuticals150 open or runningphase 3since Aug 16, 2013Aug 30, 2011none ahead
Clinique Ovo21 open or runningphase 2since Jan 30, 2019Jan 30, 2019none ahead
Dr François Bissonnette10 open or runningno phasesince Mar 8, 2018Mar 8, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Aug 30, 2011.

  1. Nov 28, 2014Phase 2 study in InfertilityFerring Pharmaceuticals · NCT02309671 · 159 enrolled · Japan
  2. Jul 13, 2017Phase 3 study in InfertilityFerring Pharmaceuticals · NCT03228680 · 373 enrolled · Japan
  3. Sep 14, 2017Phase 3 study in Controlled Ovarian SimulationFerring Pharmaceuticals · NCT03296527 · 1,011 enrolled · China, Korea, Republic of, Taiwan and more
  4. Mar 8, 2018Dr François Bissonnette’s first study: no phase study in Fertility DisordersNew to Dr François BissonnetteDr François Bissonnette · NCT03483545 · 160 enrolled · Canada
  5. May 16, 2018Phase 2 study in Controlled Ovarian StimulationFerring Pharmaceuticals · NCT03564509 · 620 enrolled · Belgium, Czechia, Denmark and more
  6. Oct 24, 20182 phase 3 studiesFerring Pharmaceuticals · NCT03740737, NCT03738618
  7. Jan 7, 2019Phase 3 study in Infertility, FemaleFerring Pharmaceuticals · NCT03809429 · 437 enrolled · Austria, Denmark, Israel and more
  8. Jan 30, 2019Clinique Ovo’s first study: phase 2 study in InfertilityNew to Clinique OvoClinique Ovo · NCT03830723 · 110 enrolled · Canada
  9. Nov 1, 2019Phase 1 study in InfertilityFerring Pharmaceuticals · NCT04150861 · 24 enrolled · China
  10. Feb 8, 2021Phase 3 study in InfertilityFerring Pharmaceuticals · NCT04773353 · 220 enrolled · India
  11. Nov 16, 2021Phase 3 study in InfertilityFerring Pharmaceuticals · NCT05263388 · 302 enrolled · Austria, France, Italy and more
  12. May 30, 2022Phase 2 study in Male Idiopathic InfertilityFerring Pharmaceuticals · NCT05403476 · 4 enrolled · United States, Belgium, Denmark and more
  13. Dec 6, 2023Phase 3 study in Infertility, FemaleFerring Pharmaceuticals · NCT06173869 · 301 enrolled · China
  14. May 21, 2025Phase 2 study in IVFClinique Ovo · NCT06997900 · 200 planned · Canada

TargetBeta

FSHR →read by rule
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule

Other programs on FSHR

ProgramCompanyFurthest phaseStudies
follitropin alfaruleMerck KGaA, Darmstadt, Germanyphase 426
Follicle Stimulating Hormoneruleglycotope-gmbhphase 46

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06997900IVF · Canada2RecruitingClinique OvoAug 2026200
NCT06173869Infertility, Female · China3CompletedFerring PharmaceuticalsMay 31, 2025301
NCT05403476Male Idiopathic Infertility · United States, Belgium, Denmark and more2TerminatedFerring PharmaceuticalsOct 5, 20244
NCT05263388Infertility · Austria, France, Italy and more3CompletedFerring PharmaceuticalsApr 16, 2024302
NCT04773353Infertility · India3CompletedFerring PharmaceuticalsDec 12, 2023220
NCT04150861Infertility · China1CompletedFerring PharmaceuticalsNov 28, 201924
NCT03830723Infertility · Canada2CompletedClinique OvoJan 20, 2021110
NCT03809429Infertility, Female · Austria, Denmark, Israel and more3CompletedFerring PharmaceuticalsFeb 16, 2022437
NCT03740737Infertility · United States3CompletedFerring PharmaceuticalsNov 11, 2020579
NCT03738618Infertility, Female · United States3CompletedFerring PharmaceuticalsDec 21, 2020588
NCT03564509Controlled Ovarian Stimulation · Belgium, Czechia, Denmark and more2CompletedFerring PharmaceuticalsOct 21, 2019620
NCT03483545Fertility Disorders · Canada–CompletedDr François BissonnetteJul 31, 2019160
NCT03296527Controlled Ovarian Simulation · China, Korea, Republic of, Taiwan and more3CompletedFerring PharmaceuticalsJan 3, 20201,011
NCT03228680Infertility · Japan3CompletedFerring PharmaceuticalsJun 10, 2019373
NCT02309671Infertility · Japan2CompletedFerring PharmaceuticalsNov 2015159
NCT01956123Infertility · Belgium, Brazil, Canada and more3CompletedFerring PharmaceuticalsMay 2015513
NCT01956110Infertility · Belgium, Brazil, Canada and more3CompletedFerring PharmaceuticalsMay 20151,329
NCT01426386Infertility · Belgium, Czechia, Denmark and more2CompletedFerring PharmaceuticalsApr 2012265

How it is read

Names in the registry

  • “Follitropin delta”, 5 entries
  • “FE 999049”, 4 entries
  • “Follitropin Delta (FE 999049)”, 3 entries
  • “Combination therapy : Follitropin delta and HP-hMG”, 1 entry
  • “REKOVELLE (Follitropin Delta)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.